organized by:

in collaboration with:

under the auspices of:

www.melanomabridge.org
info@melanomabridge.org

Virtual meeting
December 2nd - 4th
CME PROVIDER AND ORGANIZING AGENCY:

3P Solution Srl
Corso Magenta 81, 20123 Milan
Phone +39 02 36631574
www.3psolution.it
info@3psolution.it
info@melanomabridge.org

OFFICIAL LANGUAGE:
The official language is English

REGISTRATION:
This year the registration will be free of charge for all HCPs, but only registered attendees will be admitted to the meeting.

To register:
- go to: www.melanomabridge.org/registration-key-dates.php and click on REGISTER NOW
- directly through the link: www.vincentonair.com

Please, contact the Organizing Secretariat for any further information:
registration@melanomabridge.org
Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving treatments for melanoma.

The possibility to use targeted and immune-based drugs alone, in combination, or in sequence, able to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy, represent actual concepts and approaches in the clinical management of melanoma.

Melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival.

Since then, improved understanding of the tumor microenvironment and tumor immuno-evasion strategies has resulted in different approaches to target and harness the immune response. Approval of new immune- and target-therapies have further improved outcomes for patients with advanced melanoma.

The therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as radiotherapy, electrochemotherapy and surgery.

This year the Congress will start with a very actual session dedicated to the impact of the Covid-19 on daily practice both clinical and research. Latest findings in melanoma research and advances on themes of paramount importance for melanoma prevention, diagnosis and treatment, will be discussed in the two session dedicated to system biology on immunotherapy, immunogenicity and gene expression profiling and focused on the progresses of melanoma research on biomarkers/precision medicine and on combination strategies.

Then, the “Great Debate” sessions, where counterpoint views from leading experts on specific and very actual controversial clinical issues will be presented and discussed from different points of view:

- Adoptive cell therapy VS bispecific antibodies in melanoma
- MAPK inhibition VS immunotherapy on adjuvant setting in melanoma
- Could corticosteroids used for the management of side effects have an impact on the outcome of melanoma patients: Yes or No?
- PD1 combo with CTLA4 or LAG3: which one for which patient?
- Linfo-adenectomy: before or later?
- Brain metastases: do you need radiation? Yes or No
- Telemedicine VS face-to-face visit

In order to disclose and stimulate the discussion of new approaches and strategies in the field of melanoma and, based on the increasing success of “Melanoma Bridge” events over the years since 2011, a panel of international faculty will join the congress that will be held as webinar in December 2021.

Presidents of the event are Paolo A. Ascierto (National Cancer Institute, “Fondazione G. Pascale”, Naples, Italy), Iman Osman (New York University School of Medicine, New York, NY, USA), Igor Puzanov (Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA) and Corrado Caracò (National Cancer Institute, “Fondazione G. Pascale”, Naples, Italy), who will gather with the international faculty members in an interactive atmosphere which stimulates discussion and exchange of their experience regarding the most recent advances in research and clinical management of melanoma patients.
SCIENTIFIC PROGRAM

Thursday, Dec 2nd, 2021

MELANOMA BRIDGE OPENING SESSION**
Chairpersons: Paolo A. Ascierto, Francesco Marincola

07:10 pm  Lecture: A life spent for ImmunoTherapy **
Tara Withington

07:30 pm  Lecture: Integrated multi-omic functional tumor profiling for clinical decision support**
Reinhard Dummer

**Not included in the CME accredited program
SCIENTIFIC PROGRAM

Friday, Dec 3rd, 2021

09:00 am  Introduction and objectives
            Paolo A. Ascierto

SESSION
HOW COVID-19 IMPACTED ON OUR DAILY PRACTICE BOTH CLINICAL AND RESEARCH
Chairpersons: Bernard A. Fox, Igor Puzanov

09:05 am  Clinical outcomes in cancer patients with COVID-19
            Iman Osman

09:20 am  The experience at Melanoma Unit of INT Pascale of Napoli
            Paolo A. Ascierto

09:35 am  VISTA as a target for immunotherapy
            Marc S. Ernstoff

09:50 am  Addressing vulnerabilities and innovation in cancer at the time of COVID-19
            Solange Peters

10:05 am  Discussion

10:35 am  SYMPOSIUM – Optimizing Melanoma Patient Care in 2021
            Chairperson: Paolo A. Ascierto
            Translating evidence to practice: factors impacting treatment decision in melanoma BRAF+ patients, Axel Hauschild
            Digital health solutions in melanoma patient care: benefits, opportunities and challenges, Christian Blank

11:25 am  Coffee Break**

11:35 am  SYMPOSIUM – Adjuvant Therapy in Melanoma
            Chairperson: Paolo A. Ascierto
            The expanding landscape of adjuvant therapies in melanoma, Alexander M.M. Eggermont, Paolo A. Ascierto

SESSION
MELANOMA IS MODEL FOR CANCER RESEARCH
Chairpersons: Giuseppe Masucci, Magdalena Thurin

12:25 pm  Microbiota-centered interventions for the next generation I-O
            Laurence Zitvogel

12:40 pm  HLA class I defects in melanoma cells. Molecular mechanisms and clinical relevance
            Soldano Ferrone

**Not included in the CME accredited program
SCIENTIFIC PROGRAM

Friday, Dec 3rd, 2021

12:55 pm  Evaluating the cancer surfaceome: a possible strategy to identify targets and monitor immunity
           Bernard A. Fox

01:10 pm  Translational research for precision immuno-oncology in melanoma
           Olivier Michielin

01:25 pm  Gene expression profiling assays in the risk assessment of primary melanoma
           Claus Garbe

01:40 pm  Discussion

01:55 pm  Lunch**

02:45 pm  Mechanisms of success versus failure of cancer immunotherapy
           Thomas Gajewski

03:00 pm  Novel humanized mouse model to study mechanisms of immune-related toxicities
           Michelle Krogsgaard

03:15 pm  Lymphatic transport and the intersection of melanoma immunity and metastasis
           Amanda Lund

03:30 pm  A predictive model of analysis in Real World Data related to metastatic melanoma patients treated with immunotherapy
           Gabriele Madonna

03:45 pm  The state of Microbiome/Fecal Transplant
           Omid Hamid

04:00 pm  Perspectives in uveal melanoma
           Richard D. Carvajal

04:15 pm  Electrochemotherapy
           Corrado Caracò

04:30 pm  Discussion

04:50 pm  Coffee Break**

GREAT DEBATE SESSION
Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov

05:00 pm  Adoptive cell therapy VS bispecific antibodies in melanoma
           Nikhil Khushalani, Piotr Rutkowski

05:30 pm  Discussion

**Not included in the CME accredited program
MAPK inhibition VS immunotherapy on adjuvant setting in melanoma
Janice Mehnert, Caroline Robert

Discussion
SCIENTIFIC PROGRAM

Saturday, Dec 4th, 2021

GREAT DEBATE
Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov

09:00 am Could corticosteroids used for the management of side effects have an impact on the outcome of melanoma patients: Yes or No?
Georgina V. Long, Christian Blank

09:30 am Discussion

09:40 am PD1 combo with CTLA4 or LAG3: which one for which patient?
Jason J. Luke, Paolo A. Ascierto

10:10 am Discussion

SESSION EMERGENT STRATEGIES
Chairpersons: Nicola Normanno, Giuseppe Palmieri

10:20 am Neoadjuvant in melanoma
Christian Blank

10:35 am Exploring the activity of BRAF-/MEK-inhibition beyond currently approved indications
Bart Neyns

10:50 am Developing a new antibody targeting regulatory T cells in cancer
Sergio Quezada

11:05 am Stability of melanoma cell-surface PD-L1 as rate-limiting to therapeutic resistance development
Roger Lo

11:20 am Coffee Break**

11:30 am Strategies to overcome adaptive resistance to MAPK-directed therapies in melanoma
Poulkos Poulikakos

11:45 am Role of tumor metabolism
Bradley Reinfeld

12:00 pm Shall we continue to fight the dragon or try to kill its eggs?
Jean-Jacques Grob

12:15 pm Discussion

**Not included in the CME accredited program
SCIENTIFIC PROGRAM

Saturday, Dec 4th, 2021

12:30 pm   SYMPOSIUM - The role of neo-adjuvant and adjuvant immunotherapy for the treatment of patients with melanoma
Chairperson: Paolo A. Ascierto
Speakers: Jeffrey Weber, Paolo A. Ascierto

01.20 pm   Lunch**

02.10 pm   SYMPOSIUM - BRAF metastatic melanoma patients
Chairperson: Paolo A. Ascierto
Pharmacokinetics and overview on updated clinical data, Reinhard Dummer
Triple combinations and treatment sequencing, Paolo A. Ascierto

GREAT DEBATE
Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov, Alessandro Testori

03.00 pm   Brain metastases: do you need radiation? Yes or No
Sandra Demaria, Hussein A. Tawbi

03.30 pm   Discussion

03.40 pm   Telemedicine vs face-to-face visit
Allison Betof, Janice Mehnert

04.10 pm   Discussion

04.20 pm   Linfo-adenectomy: before or later?
Corrado Caracò, Jeffrey E. Gershenwald

04.50 pm   Discussion

05.00 pm   What we’ll do on Monday?
Sanjiv S. Agarwala

05.15 pm   Conclusions
Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov

**Not included in the CME accredited program
PRESIDENCY

Paolo A. Ascierto  
Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department, National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

Corrado Caracò  
Director of Melanoma and Skin Tumor Surgery, National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

Iman Osman  
Rudolf L. Baer MD Professor of Dermatology, Departments of Medicine (Oncology) and Urology, Director Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, New York University Langone, Medical School, New York, NY, US

Igor Puzanov  
Senior Vice President, Clinical Investigations Director, Center of Early Phase Clinical Trials, Chief, Melanoma Section, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

SCIENTIFIC BOARD

Sanjiv S. Agarwala  
Professor & Chief, Haematology & Oncology, St Luke’s University Hospital and Temple University, Bethlehem, PA, US

Paolo A. Ascierto  
Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department, National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

Carlo Bifulco  
Medical Director, PSJH System Genomics Laboratory, Providence St. Joseph Health, Director and Member, Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Lisa H. Butterfield  
Research Center Vice President, Parker Institute for Cancer Immunotherapy and Adjunct Professor of Microbiology and Immunology, University of California, San Francisco, CA, US

Elizabeth M. Burton  
Executive Director, Strategic Translational Research Initiative Development, The University of Texas MD Anderson Cancer Center, Houston, TX, US

Corrado Caracò  
Director of Melanoma and Skin Tumor Surgery, National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

Sandra Demaria  
Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology and Adjunct Professor at Department of Pathology, Weill Cornell Medical College and NYU School of Medicine, New York, NY, US
SCIENTIFIC BOARD

Reinhard Dummer
Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

Bernard A. Fox
Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Jerome Galon
Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

Claus Garbe
Professor of Dermatology, President of the European Association of DermatoOncology (EADO), Center for DermatoOncology Department of Dermatology Eberhard Karls University, Tuebingen, Germany

Omid Hamid
Chief of Research/ Immuno-Oncology and Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, Los Angeles, CA, US

Patrick Hwu
President & CEO, Moffitt Cancer Center, Tampa, FL, US

Giuseppe Masucci
Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

Iman Osman
Rudolf L. Baer MD Professor of Dermatology, Departments of Medicine (Oncology) and Urology, Director Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, New York University Langone, Medical School, New York, NY, US

Giuseppe Palmieri
President Italian Melanoma Intergroup (IMI), Head of Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy

Michael A. Postow
Memorial Sloan Kettering Cancer Center, New York, NY, US

Igor Puzanov
Senior Vice President, Clinical Investigations Director, Center of Early Phase Clinical Trials, Chief, Melanoma Section, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

Magdalena Thurin
Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, US

Tara Withington
Executive Director Emeritus, Society of ImmunoTherapy for Cancer (SITC), Milwaukee, WI, US

FACULTY

Sanjiv S. Agarwala
Professor & Chief, Haematology & Oncology, St Luke’s University Hospital and Temple University, Bethlehem, PA, US

Paolo A. Ascierto
Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department, National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

Allison Betof
Assistant Attending Physician, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US
FACULTY

Christian Blank  
Medical Oncology and Research Group Leader Tumor Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands

Corrado Caracò  
Director of Melanoma and Skin Tumor Surgery, National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

Richard D. Carvajal  
Director of Experimental Therapeutics and Director of the Melanoma Service, Columbia University Medical Center, New York, NY, US

Sandra Demaria  
Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology and Adjunct Professor at Department of Pathology, Weill Cornell Medical College and NYU School of Medicine, New York, NY, US

Reinhard Dummer  
Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

Alexander M.M. Eggermont  
Chief Scientific Officer, Board of Directors, Professor Surgical Oncology, Princess Máxima Center for pediatric oncology, Utrecht, The Netherlands

Marc S. Ernstoff  
Branch Chief of ImmunoOncology Branch (IOB), Developmental Therapeutics Program, Division of Cancer Therapy & Diagnosis, NCI, NIH, Bethesda, MD, US; Formerly Section Chief of Hematology/Oncology at Dartmouth College’s Geisel School of Medicine, Hanover, NH, US; and Director of the Melanoma Program at the Cleveland Clinic, Cleveland, OH, US

Soldano Ferrone  
Department of Surgery Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

Bernard A. Fox  
Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Thomas F. Gajewski  
Oncology and Immunology Professor, Department of Pathology and Department of Medicine (Section of Haematology/Oncology) - University of Chicago (Microbiome Center), Chicago, IL, US

Claus Garbe  
Professor of Dermatology, President of the European Association of DermatoOncology (EADO), Center for Dermatooncology Department of Dermatology Eberhard Karls University, Tuebingen, Germany

Jefferey E. Gershenwald  
Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston, TX, US

Jean Jacques Grob  
Professor, Head of Dermatology Department, Hopital de la Timone, Aix-Marseille, Marseille, France

Omid Hamid  
Chief of Research/ Immuno-Oncology and Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, Los Angeles, California, US

Axel Hauschild  
Professor of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Germany

Michelle Krogsgaard  
Associate Professor, Director of Tumor Immunology Program, Department of Pathology and Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, US

FACULTY

Dec 2nd - 4th, 2021  
Virtual meeting
FACULTY

Nikhil Khushalani  
Vice Chair, Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, US

Roger Lo  
Melanoma Clinic in Dermatology Member, Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, CA, US

Georgina V. Long  
Co-Medical Director Melanoma Institute Australia, Professor of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia

Jason J. Luke  
Director, Cancer Immunotherapeutics Center; Associate Professor of Medicine, UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA, US

Amanda Lund  
Associate Professor, Ronald O. Perelman Department of Dermatology, Department of Pathology, New York University Langone, Medical School, New York, NY, US

Gabriele Madonna  
Melanoma, Cancer Immunotherapy and Development Therapeutics Department, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

Francesco Marincola  
Global Head of Research, Kite Pharma, Santa Monica, CA, US

Giuseppe Masucci  
Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

Janice Mehnert  
Professor of Medicine, NYU Grossman School of Medicine, Associate Director for Clinical Research, Laura and Isaac Perlmutter Cancer Center at NYU, Director, Melanoma and Cutaneous Medical Oncology, Co-Director, Developmental Therapeutics/Phase 1, New York, NY, US

Olivier Michielin  
Head of Precision Oncology Center and Melanoma Clinic, Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland

Bart Neyns  
Head of Department, Medical Oncology, Universitair Ziekenhuis Brussel, Brussel, Belgium

Nicola Normanno  
Scientific Director, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

Iman Osman  
Rudolf L. Baer MD Professor of Dermatology, Departments of Medicine (Oncology) and Urology, Director Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, New York University Langone, Medical School, New York, NY, US

Giuseppe Palmieri  
Full Professor of Medical Oncology at University of Sassari & Head of Unit of Cancer Genetics at the Institute of Genetic and Biomedical Research (IRGB), National Research Council (CNR), Sassari, Italy

Solange Peters  
Full professor UNIL, Chair Medical Oncology Department, Head of the Specialized Thoracic Tumor Consultation, Oncology Department UNIL CHUV, Lausanne University, Physician in charge of Thoracic Tumor Center, Lausanne, Switzerland - ESMO President, Scientific Coordinator, European Thoracic Oncology Platform (ETOP), JTO Deputy Editor

Dec 2nd - 4th, 2021  Virtual meeting
FACULTY

Poulakos Poulikakos
Associate Professor, Department of Oncological Sciences, Department of Dermatology, The Tisch Cancer Institute, Icahn School of Medicine Mount Sinai, New York, NY, US

Igor Puzanov
Senior Vice President, Clinical Investigations Director, Center of Early Phase Clinical Trials, Chief, Melanoma Section, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

Sergio Quezada
Professor of Cancer Immunology and Immunotherapy, Immune Regulation & Tumour Immunotherapy Lab, CRUK Senior Cancer Research Fellow, UCL Cancer Institute, University College London, London, UK

Bradley Reinfeld
Medical Scientist Training Program, Department of Medicine, Vanderbilt University Medical Center (VUMC), Graduate Program in Cancer Biology, Vanderbilt University, Nashville, TN, US

Caroline Robert
Head of Dermatology Unit, Institut Gustave Roussy; Co-Director of Melanoma Research Unit, INSERM Paris-Sud University, Paris, France

Piotr Rutkowski
Maria Sklodowska-Curie National Research Institute of Oncology; Head of Department of Soft Tissue/Bone Sarcoma and Melanoma; Deputy Director for National Oncological Strategy and Clinical Trials, Warsaw, Poland

Hussein A. Tawbi
Deputy Chair, Department of Melanoma Medical Oncology, Director of Melanoma Clinical Research & Early Drug Development, Co-Director, MD Anderson Brain Metastasis Clinic, Melanoma Medical Oncology, Investigational Cancer Therapeutics, UT MD Anderson Cancer Center, Houston, TX, US

Alessandro Testori
Dermatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Magdalena Thurin
Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, US

Jeffrey Weber
Deputy Director, Professor of Oncology, Department of Medicine, Perlmutter Cancer Center, New York University Langone, Medical School, New York, NY, US

Tara Withington
Executive Director Emeritus, Society of ImmunoTherapy for Cancer (SITC) Milwaukee, WI, US

Laurence Zitvogel
Group Leader of Tumour Immunology and Immunotherapy of Cancer, European Academy of Tumor Immunology, Gustave Roussy, University Paris Saclay, INSERM, Villejuif Grand-Paris, France
CONTINUING MEDICAL EDUCATION
3P Solution has been accredited by the Ministry of Health as a CME Standard Provider (code 327, authorized on October 15th, 2012).
3P Solution owns the responsibility for the content, quality and ethical correctness of this CME activity.
Melanoma Bridge congress has been accredited (ID CME 335005) with 22,5 CME credits with a formative technical-professional objective “Technical professional content (knowledge and competences) specifications of each profession, of all specialization and ultra-specialist activity. Rare diseases”, belonging to formative technical-professional objective area, for the following professions: medical doctors, pharmacists, biologists, nurses.
In order to receive credits, participants must:
1. Attend at least 90% of the accredited CME sessions (attendance check);
2. Complete the CME test by answering at least 75% of the questions correctly
3. Complete the evaluation form

MY ECM
Age.na.s activated MyEcm service (personalized page available to any health professional), which enables you to:
1. Consult the CME events offer;
2. Refer to the summary of events attended and earned credits;
3. Provide an assessment of courses organized by the Provider.
To access online services please log on to http://ape.agenas.it/professionisti/myecm.
If this meeting fulfilled your expectations, please click on 👍 and give your assessment.
Melanoma Bridge is sponsored by an unrestricted grant from:

**PLATINUM SPONSOR**

| MSD |

**GOLD SPONSOR**

| Bristol Myers Squibb™ |

| NOVARTIS |

**SILVER SPONSOR**

| IMMUNOCORE |

| oncosec™ |

**SPONSOR**

| IGEA Clinical Biophysics |

| natera® |

| NEKTAR® |

| Pierre Fabre Oncology (a division of Pierre Fabre Pharma) |